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Emerging evidence is showing nutrition as a crucial factor in the high prevalence
and incidence of neurodegenerative mental disorders. Preventive interventions on
neuroinflammation seem to be able to interfere with neurodegeneration. Supplementation
of essential nutrients, such as long-chain-polyunsaturated fatty acids, vitamin E and
mineral elements, may minimize inflammation, enhancing antioxidative defense, and
lowering the risk and incidence of age-related diseases, such as cardiovascular diseases
and neurodegenerative diseases. This manuscript reviews the current evidence on
the role of neuroinflammation in the pathophysiology of neurodegenerative and mental
disorders, and preventive strategies for food supplementation in these neuropsychiatric
diseases. Dietary supplementation-based strategies have been demonstrated to be
effective in subjects with mild cognitive impairment, while weaker results have
been obtained in patients with advance neurodegenerative disease. Adjunctive
supplementation has also been demonstrated to improve depression, this being of
marked benefit considering the comorbidity between cognitive impairment/dementia
and depression. Further research is needed to improve the prescriptive precision of
supplementation in patients, and to better understand potential interactions with clinical
and pharmacokinetic factors.
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INTRODUCTION
Cognitive impairment is a relevant manifestation of neurodegenerative diseases, which are
a heterogeneous group of nervous system conditions, including Alzheimer’s disease (AD),
Parkinson’s disease, Lewy body dementia, and vascular dementia (1). These disorders are
characterized pathologically by the abnormal deposition of proteins throughout the brain and
spinal cord; glial activation; increased neuroinflammation and changes in metabolic functions of
the central and peripheral nervous system (1). Clinical manifestations of these conditions, such
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as depression and dementia, afflict a growing population
worldwide and represent a significant healthcare, social and
public policy burden. As an example, over 50 million people
live with dementia in the world today and this number is
projected to increase to 152 million by 2050 (2). In fact, dementia
is considered a mental health issue, with neuropsychiatric
symptoms, including depression. The actual prevalence of this
latter manifestation can be high in AD patients, with great
variability of estimates across studies according to criteria,
ranging from 13% (3) to up to 97% (4). Moreover, depression
occurring in mid-life or across the lifespan is associated with an
increased risk of dementia (5).
Brain vulnerability is influenced by both non-modifiable and
modifiable risk factors, including age, family history and genetics
on one hand, and preventable cardiovascular risk, obesity,
diabetes, sleep apnea, physical activity, tobacco/alcohol/drugs,
and stress, on the other hand (6, 7). Diet is one of the most
important lifestyle-related factors which may impact on brain
vulnerability. Emerging evidence is showing nutrition as a
crucial factor in the high prevalence and incidence of mental
disorders suggesting that diet is important to brain health as
much as to the health of other physiological systems, such
as the cardiovascular, endocrine, and digestive systems (8).
Micronutrients, such as vitamins and trace mineral elements,
are involved in every cellular/biochemical process and play
important roles in the brain and heart function, immunological
responses, and antioxidant defense systems. Low levels of
micronutrients reduce the activity of antioxidant enzymes,
which may lead to DNA, protein, and fatty acid oxidation
and crosslinking, along with mitochondrial ATP depletion,
therefore contributing to cardiovascular or neurodegenerative
disorders (9). n-3 Polyunsaturated fatty acids are involved
in the maintenance of cognitive functions, promoting adult
neurogenesis and neuronal plasticity through the modulation of
membrane remodeling, inflammatory mediators and oxidative
stress (10).
Growing evidence shows that the release of pro-inflammatory
cytokines and mediators in the nervous system is associated with
persistent stress stimuli and may lead to neuronal dysfunction
and death (11–14). Recent studies also highlight the role of
the gut microbiota in many neurodegenerative diseases, as a
“microbiota–gut–brain axis” would synchronize the gut with the
central nervous system (CNS) and modify the behavior and brain
immune homeostasis (15).Modulation of the gutmicrobiotamay
be a tractable strategy for developing novel strategies for complex
CNS disorders (16). Supplementation of essential nutrients,
such as long-chain polyunsaturated fatty acids (LC-PUFAs),
vitamin E and mineral elements, may minimize inflammation
and enhance antioxidative defense. Consequently, it may lead to
lowering the risk and incidence of age-related diseases, including
neurodegenerative diseases.
This manuscript reviews the current evidence on
the role neuroinflammation in the pathophysiology of
neurodegenerative and mental disorders, and nutrient based





Functional and cognitive impairments featuring dementia, in
particular AD, vascular dementia and Parkinson’s disease, have
been associated with depression (17, 18). Concurrent preclinical
and clinical evidence has suggested in recent years that in a
subset of patients, inflammatory processes and decreased cerebral
levels of neurotrophic factors might play some role in the
complex pathogenesis of depression (19). Volume reduction
of the hippocampus was also observed in AD and depressed
patients, and this morphological alteration was related to
stress exposure, known to impair the dendritic complexity of
the neurons in the CA3 subfield of the hippocampus and
affects neurogenesis in the dentate gyrus (20–22). Oxidative
stress plays a role in the pathophysiology of depression in
bipolar disorder, and high levels of lipid peroxidation in the
blood correlates with decreased dentate gyrus volume (23).
The notion that depression, as well as infection, encompasses
symptoms, such as malaise, anhedonia, decreased social behavior,
decreased motor activity, sleep abnormalities and fatigue, which
are collectively referred as “sickness behavior,” also suggests
the involvement of inflammatory processes in depression
development. Such symptoms are confirmed by acute occurrence
of depressive symptoms in healthy volunteers administered
with lipopolysaccharide (24). Stress syndrome—that is, elevated
cortisol levels—has been observed in up to 70% of patients with
depression, and also in AD pathology (25).
The role of inflammation in the pathogenesis of
depression is supported by studies showing increased levels
of proinflammatory cytokines, such as IL-1β, IL-6, IL-12, TNF-α,
and prostaglandin E2 (PGE2), in patients with depression
(26, 27), and by some experiments in preclinical models in
which the administration of inflammatory cytokines promoted
a depressive-like syndrome (28, 29). Though it should be noted
that inflammation occurs in a sub-set of people with depression
and is not always apparent via cytokine blood assays (30).
Both depression and heart disease have been linked to the
impairment of the cholinergic anti-inflammatory pathway and
have been proposed as clinical manifestations of one underlying
mechanism (31, 32).
Persistent stress stimuli have, however, been observed to
induce the synthesis and the release of pro-inflammatory
cytokines and chemokines, such as IL-1β, mainly by neurons and
the macrophage–monocyte line, including microglia, resulting
in increased expression of inducible nitric oxide synthase
and cyclooxygenase. Hydrogen peroxide acts as a cell-to-cell
messenger, in the process of inflammatory responses induced
by oxidative stress (33). In addition, neurons and glial cells can
produce proinflammatory cytokines, such as IL-1β, IL-6, and
TNF-α (11, 14, 34, 35).
One further mechanism of depression is a deficit of
neurotrophic factors, such as brain-derived neurotrophic factor
(BDNF), which leads to altered synaptic plasticity and then to
neuronal dysfunction and cell death (18, 36). Inadequate supply
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of trophic factors also affects neurogenesis, reducing the number
of neuronal stem cells able to multiply and differentiate. Several
studies on stressed rodents and on patients with depression
detected decreased levels of BDNF, together with abnormalities in
the levels of neurotransmitters and neuroendocrine dysfunction
(18). In humans, it was also reported that BDNF decreases with
age and that higher levels of BDNF correlate with better cognitive
performance in older adults (36).
The Role of Microglia
It has been observed that morphological and functional
alterations of the microglia appear in adults suffering from
depression. Such findings were also replicated in numerous
experimental animal models subjected to chronic stress where
high levels of proinflammatory cytokines were found to be
secreted mainly by activated microglia within the brain.
Moreover, an elevated level of microglia activation was detected
in individuals with depression who had committed suicide (37).
A microglial signature dependent on TGF-β signaling was
demonstrated and was found to be activated by any type of
pathologic event or change in brain homeostasis (38). Microglia
can strongly influence the pathologic outcome or response
to a stressor due to the release of a plethora of substances,
including cytokines, chemokines and growth factors. A diversity
of microglia phenotypes has been described in response to health,
aging, disease, and lifestyle (39). Consequently, the activation
of microglia with release of cytokines and neuroinflammation
takes place in some individuals and not in others (40).
Briefly, catecholamines released during stress bind to receptors
expressed by innate immune cells, this binding induces the
synthesis and release of inflammatory cytokines that stimulate
the production of corticotropin-releasing factor (CRF) by the
hypothalamic paraventricular neurons. CRF transported by
portal hypophyseal circulation targets the adenohypophysis
leading to the release of adrenocorticotropic hormone (ACTH)
that binds to adrenal glands to induce cortisol release. Cortisol
has a double paradoxical effect: it has anti-inflammatory activity
in the periphery and pro-inflammatory activity at the CNS level,
where specific receptors are present within the hippocampus and
amygdala. Stress conditions, as well as an exogenous application





Since food is one of the most important lifestyle factors
accounting formental health, one of the strategies currently being
developed to treat depression, as well as AD, is to administer
compounds with anti-inflammatory and antioxidant activity,
capable of crossing the blood–brain barrier, and targeting cells
and the molecular players of neuroinflammation. The relevance
of this attempt is confirmed by evidence that treatment with
anti-inflammatory drugs had beneficial effects on patients with
major depression, although some studies failed to demonstrate
that COX-2 inhibitors had an activity superior to placebo,
most likely due to the fact that COX inhibitors do not affect
the expression of pro-inflammatory cytokines and chemokines
(44–47). As it is known that natural compounds present in
plant-based foods, such as fruits (especially berries), display
anti-inflammatory neuroprotective activity, nutritional protocols
aiming at counteracting the progression of chronic diseases have
been proposed (48–57). Interest has also focused on dietary
patterns, such as feeding time and circadian rhythms, to increase
availability of bioactive compounds capable of exerting both anti-
inflammatory and antioxidant functions. The field of “nutritional
psychiatry” aims to describe and understand the relationship
between dietary factors and mental health disorders (10, 58).
n-3 LC-PUFAs (a.k.a. omega-3) are precursors of a series of
lipid mediators, including resolvins, protectins and maresins,
which are collectively termed “specialized pro-resolving
mediators” (SPM), and which terminate inflammatory processes
blocking polymorphonucleate migration and promoting
macrophage M2 switch (59). Several preclinical and clinical
studies have shown that n-3 LC-PUFAs are involved in the
maintenance of cognitive functions acting on membrane
remodeling, inflammation mediators and oxidative stress.
They are considered beneficial for the CNS via the modulation
of adult neurogenesis, synaptic and neuronal plasticity, and
microglia activation (10). Docosahexaenoic acid (DHA) is
a key structural component of membrane phospholipids in
the brain and eicosapentaenoic acid (EPA) is a precursor of
anti-inflammatory cytokines, an inhibitor of prostaglandins,
thromboxanes and leukotrienes. In contrast, linoleic acid, a n-6
LC-PUFA (a.k.a. omega-6), is a precursor of the inflammatory
mediator arachidonic acid (10). DHA is 250–300-times more
abundant in brain tissue compared to EPA (60). It is known that
EPA and DHA can cross the blood–brain barrier by diffusion and
by blood-brain barrier transporters (61). The latter mechanisms
could be defective in aged people or subjects with related
genotypes, such as APOE4, suggesting higher requirements in
population subgroups (62).
DHA intake has been related to lower rates of incident
dementia. In populations with higher dietary intake of DHA
and higher concentrations of plasma DHA there is a lower
risk of cognitive impairment (61). In addition, peripheral
blood macrophages obtained from patients with mild cognitive
impairment (MCI) and AD, were unable to accomplish an
effective phagocytosis for Aβ peptide (the main component
of the amyloid plaques in AD), unlike macrophages obtained
from healthy controls which could recover phagocytic functions
via n-3-LC-PUFA. Recent studies of fish-derived omega-
3 supplementation in patients with AD and MCI have
shown polarization of APOE3/E3 patients’ macrophages to an
intermediate M1–M2 phenotype that is optimal for Aβ peptide
phagocytosis and the stabilization of cognitive decline (63, 64).
Moreover, DHA can increase neuronal membrane fluidity
and decrease membrane peroxidation by reducing cholesterol
levels in the cell membrane, which leads to reduced oxidative
stress in the cerebral cortex and in the hippocampus (65, 66).
DHA red blood cell content has been related with memory
performance, as 2.4 g of EPA plus DHA/day significantly
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improved red blood cell membrane EPA+DHA composition in
older adults with memory impairment, and working memory
and neuronal response were concomitantly improved (66).
Other clinical trials showed different outcomes of the omega-
3, such as EPA, docosapentaenoic acid (DPA), and DHA,
supplementation, suggesting its effectiveness in the prevention
of dementia although not in the treatment of overt dementia
(65); this probably is in relation to the different genotypes of
the subjects included in the trial (e.g., carriers of the E4 allele)
(67). Dietary supplementation of EPA, DPA, and DHA in aged
rats restored reduced depolarization-induced transmitter release,
by changing the membrane composition, while healthy human
adults who received EPA supplementation have decreased serum
proinflammatory cytokines levels (59, 68).
Great interest was also focused on the properties of some
compounds to exert an antioxidant activity, such as vitamin E,
and on the ability to interfere with one carbon metabolism by
decreasing the quantities of homocysteine, such as the B vitamins
(49). Administration of vitamin E at 2,000 IU/day was reported to
slow functional decline in mild and mild to moderate AD, while
it had no effect on subjects with MCI (69). Moreover, preclinical
studies have reinforced the hypothesis of an antidepressant-like
response of vitamin E, as the mechanisms underlying its effect
seem to be related to the modulation of oxidative stress and
neuroinflammation (70).
VARIABILITY IN RESPONSE TO
NUTRACEUTICALS INTAKE: THE ROLE OF
THE GUT–BRAIN AXIS AND THE
MICROBIOME DURING AGING AND
NEURODEGENERATIVE DISEASES
Although dietary supplements can be obtained and consumed
without medical prescription, criteria should be necessary to
identify patients affected with neurodegenerative diseases who
would most benefit from such an approach. As an example, a
meta-analysis of randomized controlled trials (RCT) found that
higher intake of the omega-3 EPA and DHA improved specific
cognitive domains in subjects with MCI without dementia but
had no effects in healthy adults and those with AD (71).
This suggests that people in the early stages of progression of
cognitive decline and depression may benefit from treatment
with omega-3, but that advanced disease is not susceptible to
improvement. So, eligible patients need to be identified when
such supplementation is proposed in a clinical setting. In this
respect, a clinical trial carried out in elderly people with MCI
demonstrated beneficial effect of B-vitamin treatment on brain
atrophy rate of adults with MCI, only in subjects with high
plasma n-3 LC-PUFAs (72). Of note, it has been observed that
when the omega-3 fatty acids DHA and EPA concentrations are
low, vitamin B treatment has no effect on cognitive decline in
MCI, but when omega-3 levels are in the upper normal range,
vitamin Bs interact to slow cognitive decline (73).
It is known that gut microbes are a relevant factor
changing the effect of dietary supplements on the brain.
The exposome represents all exogenous and endogenous
environmental exposures of whichmicrobiota, genes and lifestyle
environment, may determine the metabolism associated with a
specific phenotype. It is known that our microbiome is changing
with growing age. Indeed, both cell culture-dependent and -
independent studies show that the gut microbiota of older
people differs from that of younger adults (74). There is no
chronological threshold or age at which the composition of the
microbiota suddenly alters; rather, changes occur gradually with
time. O’Toole and Jeffery (75) showed that the gut microbiota
of older people differs from that of younger adults and may
modulate aging-related changes in innate immunity, sarcopenia
and cognitive functions.
Accumulating evidence now indicates that the gut microbiota
also communicates with the CNS, possibly through neural,
endocrine and immune pathways, and thereby influences brain
function and behavior (11). Thus, the emerging concept of a
microbiota–gut–brain axis suggests that modulation of the gut
microbiota may be a tractable strategy for developing novel
therapeutics for complex CNS disorders (16).
The Human Microbiome Project and subsequent studies
using next-generation sequencing technology have highlighted
that thousands of different microbial species are present in the
human gut, and that there has been a significant variability of
taxa in themicrobiota composition among people. Several factors
(gestational age, mode of delivery, diet, sanitation, and antibiotic
treatment) influence the bacterial community in the human
gastrointestinal tract, and among these, dietary components, such
as n-3 fatty acids, fibers and polyphenols, play a crucial role
(76, 77).
A bidirectional communication between the gut and the
brain occurs via the immune system, the vagus nerve,
the enteric nervous system and microbial metabolites (78).
Substances, including short-chain fatty acids (SCFAs), proteins
and tryptophan metabolites, exchanged through the circulatory
system, affect mood, cognition and other brain function
parameters (15, 16).
It is important to consider that gut microbes can produce
neurotransmitters, such as dopamine, 5-HT, GABA, and
acetylcholine (16). These neurotransmitters may signal to the
brain via the vagus nerve. In particular, gut microbes can
stimulate immune cells to produce cytokines. These cytokines
might target the brain via blood vessels of the circulatory system.
In addition, gut microbes can produce metabolites, such as
microbial fermentation end-products (SCFAs, e.g., butyrate) that
can regulate the epigenetic synthesis of BDNF, for example (79,
80). These metabolites can potentially migrate to the brain via
the blood vessels or may stimulate gut epithelial cells to produce
neurotransmitters that activate the vagus nerve (16).
Activity of the gut–brain axis seems to be linked to certain
genetic variations. One example is the apolipoprotein E4
(APOE4) genotype which has been associated with early cognitive
decline and is the strongest prevalent genetic risk factor for
AD. Apolipoprotein E is a transporter of cholesterol and it is
present in the liver (80–90%), in the brain glia and macrophages.
It was found to influence the structure and the function of
the gut microbiome both in humans and mice (81, 82). This
suggests that the gut–brain axis is a potential target to reduce
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the impact of the APOE4 allele on cognitive decline and for
the prevention of AD (81). For example, fecal microbiota
amplicon sequencing from age- and BMI-matched individuals
revealed higher levels of Prevotellaceae in APOE3/E3 carriers
relative to other genotype subgroups, whereas higher levels of
Ruminococcaceae were correlated with the APOE2/E3 genotype
relative to APOE4 carriers. Ruminococcaceae are involved in the
production of SCFAs, such that their depletion is causally linked
to inflammation (83). These findings therefore suggest that these
bacteria might contribute to the protective effects of APOE2 and
APOE3 alleles against AD relative to the APOE4 genotype (81).
As a confirmation of these concepts, it has been observed that
fish oil intake works better in non-APOE4 carriers. Huang et al.
(84) highlighted that consumption of fatty fish was associated
with a reduced risk of dementia and AD for those without the
APOE4 allele. Quinn et al. (85) performed a randomized, double-
blind, placebo-controlled trial to determine that supplementation
with DHA slows cognitive and functional decline in individuals
with AD. Participants were randomly assigned to algal DHA
at a dose of 2 g/day or to placebo for a duration of treatment
of 18 months. Overall, supplementation with DHA compared
with placebo did not slow the rate of cognitive and functional
decline in patients with mild to moderate Alzheimer disease,
but while there was no DHA treatment effect on any outcome
measure in the APOE4-positive group, those receiving DHA in
the APOE4-negative group had a significantly lower decline in
mean change in Alzheimer’s Disease Assessment Scale-Cognitive
Subscale score over 18 months vs. placebo group.
More recently, Arellanes et al. (86) demonstrated that
supplementation with DHA doses higher than 1 g per day
may contribute to reducing certain biomarkers associated with
dementia prevention. High doses of DHA are needed for
adequate brain bioavailability and APOE4 is associated with
reduced delivery of DHA and EPA to the brain before the
onset of cognitive impairment. A total of 33 individuals were
provided with two vitamin B complex supplements per day (each
containing 500 µg of vitamin B12, 50mg of vitamin B6, and
400 µg of folic acid) and randomized to 2,152mg of DHA per
day or placebo over 6 months. There was a significant increase
in cerebrospinal fluid (CSF) DHA in the DHA supplement
arm compared with placebo. It was also observed that a trend
for a greater increase in CSF DHA in APOE4 non-carriers
compared with carriers occurred (but the interaction between
the treatment group and APOE group on the change of CSF
DHA was not significant). CSF EPA levels were increased after
DHA supplementation, with such results being in line with
previous reports (87). However, change in CSF EPA levels in
both groups was significantly greater in APOE4 non-carriers
compared to carriers.
As mentioned earlier, EPA and DHA are able to produce
SPMs such as RvE1, RvE2, and RvD1, RvD2, respectively, that are
involved in the resolution of inflammation (88). Martinsen et al.
quantified cortical and hippocampal fatty acid, and phospholipid
profiles along with select EPA- and DHA-derived SPMs in 2-, 9-
and 18-month-old APOE3 and APOE4 male and female mice.
A 10% lower cortical DHA was evident in APOE4 females at
18 mo compared with 2 mo, with no significant decrease in
APOE3 or APOE4 males. This decrease was associated with
a reduction in DHA-phosphatidylethanolamine. In addition,
although no sex∗APOE genotype interactions were observed for
SPMs expressed as a ratio of their parent compound, higher
cortical RvD3, neuroprotectin D1 (NPD1), maresin 1 (MaR1)
were evident in females, and lower cortical 17R-resolvin D1, 10S,
17S-diHDHA, and 18-HEPE in APOE4 (88).
Presented evidence suggests that precision medicine
represents a future perspective for treatment and prevention
of neurodegenerative diseases. Genetics, nutrigenetics, and
pharmacogenetics have a major role in health maintenance and
treatment of diseases. In particular, a genomics, transcriptomics,
and epigenomics approach could be useful, and the potential
advantages of a genotype-based personalized nutrition could
facilitate early, personalized therapy, and improve motivation.
THERAPEUTIC OPPORTUNITIES FOR
FOOD SUPPLEMENTS IN DEPRESSION:
EVIDENCE, LIMITATIONS AND
SUGGESTIONS FOR THE FUTURE
Evidence for the potential efficacy of several supplementation
strategies in the prevention and treatment of neurodegenerative
diseases has been obtained in clinical trials, although inconsistent
results were produced. A systematic overview of all available
top-tier meta-analyses of RCTs reported on the efficacy of
nutrient supplements in patients with common and severe
mental disorders (89). In particular, 33 unique meta-analyses
with outcome data from placebo-controlled trials were included
from a total of 10,951 participants. Results highlighted that
omega-3 LC-PUFA, EPA at dose up to 4,400 mg/day (on average
1–2 g of EPA per day) in particular, is significantly effective in
depression. Moreover, good evidence supported the effectiveness
of high dose of methyl folate (15 mg/day) compared with folic
acid and zinc as an adjunctive treatment in major depressive
disorder (MDD) (89).
Nevertheless, some clinical trials failed to demonstrate
the efficacy of LC-PUFA, either alone or associated with
pharmacological or behavioral interventions, in patients with
depression (90–93).
Unpromising results were also obtained by some
authors researching the impact of the impact of LC-PUFA
supplementation on cognitive functions (94–96). In some
instances, clinical trials tested complex interventions and
obtained data which may be difficult to interpret. As an
example, Chew et al. evaluated the effects on cognitive function
of oral supplementation with 1 g LC-PUFA and/or lutein
10 mg/zeaxanthin 2mg in elderly subjects with age-related
macular degeneration and failed to demonstrate efficacy of
supplementation (97).
It is possible that multinutrient combinations may provide
some advantage, with possible favorable synergistic interactions
between components. For example, a recent 36-month,
double-blind, placebo-controlled study in 311 participants
with prodromal AD reported that a multinutrient intervention
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containing DHA and EPA slowed decline of cognition, function,
brain atrophy, and disease progression (98).
It has been observed that adjunctive use of nutraceuticals has
the potential to modulate several key neurochemical pathways
and can be used as an augmentation strategy to improve
inadequate response to antidepressants. In this application, a
systematic review and meta-analysis found primarily positive
results for replicated studies testing adjunctive S-adenosyl
methionine (SAMe), methyl folate, n-3 LC-PUFAs (EPA or ethyl-
EPA), and vitamin D; positive isolated studies found efficacy of
creatine and an amino acid formula; mixed results were found for
zinc, folic acid, and vitamin C; and negative results were found for
inositol (99).
Folate deficiency has been reported in approximately one-
third of people suffering from depressive disorders (99).
A combined folate, B12 and B6 dietary deficiency, induces
hyperhomocysteinemia and imbalance of S-adenosylmethionine
and S-adenosylhomocysteine, leading to an up-regulation of
presenilin1 (PS1) and beta-secretase (BACE) and amyloid beta
deposition, promoting progression to AD (100). Several studies
tested folic acid adjunctively with antidepressants and most of
these studies yielded positive results in regard to enhancing either
antidepressant response rates or increasing response onset. The
5-methlytetrahydrofolate (dosage 400 µg to 15mg) or folinic
acid (400–800 µg) are considered safe and potentially effective
forms (99).
Available data regarding the adjunctive use of n-3 LC-PUFAs
in depression are in favor of n-3 compared with placebo. A
recent network meta-analysis of 10 clinical trials including 910
patients, demonstrated that adjuvant supplementation with n-3
PUFAs was superior on MDD symptoms in comparison with
placebo, and that high dose n-3 PUFAs (SMD: 0.908± 0.331; 95%
CI: 0.262–1.581) were more effective than low dose n-3 PUFAs
(SMD: 0.601± 0.286; 95% CI: 0.034–1.18) (101).
A recent key study, Mischoulon et al. (102), evaluated 196
patients with MDD who were administered with EPA 1 g/day or
DHA 1 g/day or placebo for 8 weeks. Significant improvement
in depression symptoms as measured by the 17 -item Hamilton
Rating Scale (HAM-D-17), the Quick Inventory of Depressive
Symptomatology–Self-report (QIDS-SR) and the Clinical Global
Impression—Severity scale (CGI-S) was observed but neither
active treatment reached statistical significance compared to
placebo, with the response rates being 40–50% for each arm with
a remission of ∼30%. The authors of the study concluded that
neither EPA-enriched nor DHA-enriched n-3 was superior to
placebo for the treatment of MDD, hypothesizing that baseline
levels of inflammatory and metabolic markers, such as human C-
reactive protein, IL-6, IL-1RA, leptin, and adiponectin could have
an impact on response (102).
Rapaport et al. (103) explored in a post-hoc analysis of
the above study, whether inflammatory biomarkers act as
moderators of clinical response to omega-3 fatty acids in
subjects with MDD. It has been observed that, overall, although
treatment group differences were negligible (standardized
treatment effect size, ES: −0.13–0.04), subjects with “high”
inflammation improved more on EPA than placebo (ES:
−0.39) or DHA (ES: −0.60) and less on DHA than placebo
(ES: 0.21). Furthermore, difference between EPA and placebo
effect increased with increasing numbers of markers of high
inflammation. Therefore, the authors concluded that employing
multiple markers of inflammation facilitated the identification of
a more homogeneous cohort of subjects with MDD responding
to EPA with an advantage over placebo.
A post-hoc analysis of an 8-week, double-blind, RCT (n= 158)
investigated a combination of nutraceuticals comprising omega-
3 (EPA 1 g/DHA 656mg), SAMe, zinc, 5-hydroxytryptophan,
folinic acid, and co-factors vs. placebo for the treatment of
MDD. The study explored levels of PUFAs, folate, vitamin
B12, zinc, homocysteine and BDNF as possible predictors and
correlates of response to nutraceutical supplementation. It has
been demonstrated that concentrations of EPA and DHA in red
cell membranes increased in response to treatment and were
significantly correlated with a decrease in depressive symptoms
during active treatment (p = 0.003 and p = 0.029, respectively).
Higher baseline levels of omega-3 fatty acid also correlated with
depression reduction in the active treatment group (p = 0.011)
(99). Therefore, changes in fatty acid levels resulting from a
nutraceutical combination containing EPA and DHA provided a
biomarker response in treating depression (99).
A subcommittee of the International Society for Nutritional
Psychiatry Research organized an expert panel and developed
a consensus-based practice guideline for clinical use of n-3
LC-PUFAs in MDD (104). Although a link between low
omega-3 levels and depressive symptoms was acknowledged,
evidence for supplementation as a prevention strategy was
not sufficient. Stronger evidence was found for adjunctive
supplementation with antidepressants, and acute use in the
presence of obesity or inflammation was deemed as a potentially
more effective treatment strategy. Evidence for efficacy of
omega-3 supplementation in bipolar disorder was present, while
evidence for use in children or elderly was not strong. Application
in perinatal usage was based on weak evidence but omega-3
were indicated as safer than antidepressants (105). With respect
to formulation and dosage, both pure EPA or an EPA/DHA
combination of a ratio higher than 2 are considered effective, and
the recommended dosages should be 1–2 g of net EPA daily, from
either pure EPA or an EPA/DHA (>2:1) formula.
Current evidence most strongly supports a positive
association between zinc deficiency and the risk of depression
(106–108). Conversely, the relationship between magnesium
and selenium deficiency and depression has not been fully
understood. Several hypotheses have been advanced, and
selenium andmagnesium seem to be involved in the regulation of
the hypothalamic–pituitary–adrenal axis, and of glutamate (109).
Owen et al. (110) measured plasma vitamin E (α-tocopherol)
in 49 adults with major depression. It has been observed that
subjects had significantly lower plasma vitamin E (4.71 ± 0.13
µmol/mmol cholesterol) than has previously been reported for
healthy patients, and plasma vitamin E was inversely correlated
to depression score. In addition, alpha tocopherol was found
to be beneficial in mild to moderate AD by slowing decline of
cognition (69).
In conclusion, good evidence supports the efficacy of
adjunctive supplementation with EPA, vitamin D, and methyl
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folate in patients with depression, and mixed results are available
for zinc and vitamin C.
CONCLUSION
Neuroinflammatory mechanisms based on glial cell
inflammatory processes and resulting neuronal dysfunction
and impaired neurogenesis have been identified (106). Several
neurodegenerative conditions have been linked to persistent
oxidative stress, and pathological changes dependent on release
of inflammatory mediators. In addition, the role of some
nutrients, namely DHA and EPA among others we have not
reviewed, in the regulation of microinflammation and central
neurotransmission has been elucidated. Therefore, great interest
has focused on diet and eating habits which may provide suitable
levels of bioactive compounds capable of exerting both anti-
inflammatory and antioxidant functions, and their therapeutic
potential to prevent neurodegenerative diseases and one of their
prodromes, clinical depression.
Dietary supplementation-based strategies have been
demonstrated to be effective in people with depression and
in those with MCI, while weaker results have been obtained in
patients with advanced neurodegenerative disease.
When addressing prevention and treatment of
neuroinflammation-dependent conditions by dietary
supplementation, beyond the identification of required nutrients,
it is necessary to evaluate substance metabolism, absorption
and distribution, namely into the CNS, and the interaction with
subject’s feature including genetic variation and microbiota. The
emerging concept of a microbiota–gut–brain axis suggests that
modulation of the gut microbiota may be a tractable strategy for
developing novel therapeutics for complex CNS disorders, and
dietary habits play a crucial role in the selection of the bacterial
community in the human gastrointestinal tract (77).
Future research ideally should focus on precision-
based approaches tailoring supplementation based on
nutrient deficiencies, neurochemical abnormalities or
pharmacogenetic differences.
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9. Kazmierczak-Barańska J, Boguszewska K, Karwowski BT. Nutrition
can help DNA repair in the case of aging. Nutrients. (2020)
12 :3364. doi: 10.3390/nu12113364
10. Godos J, Currenti W, Angelino D, Mena P, Castellano S, Caraci F, et al. Diet
and mental health: review of the recent updates on molecular mechanisms.
Antioxidants. (2020) 9:346. doi: 10.3390/antiox9040346
11. Ricci S, Fuso A, Ippoliti F, Businaro R. Stress-Induced cytokines and
neuronal dysfunction in alzheimer’s disease. J Alzheimers Dis. (2012) 28:11–
24. doi: 10.3233/JAD-2011-110821
12. Munhoz CD, García-Bueno B, Madrigal JLM, Lepsch LB, Scavone
C, Leza JC. Stress-induced neuroinflammation: mechanisms
and new pharmacological targets. Braz J Med Biol Res. (2008)
41:1037–46. doi: 10.1590/S0100-879X2008001200001
13. Nogovitsyn N, Muller M, Souza R, Hassel S, Arnott SR, Davis
AD, et al. Hippocampal tail volume as a predictive biomarker of
antidepressant treatment outcomes in patients with major depressive
disorder: a CAN-BIND report. Neuropsychopharmacology. (2019)
45:283–91. doi: 10.1038/s41386-019-0542-1
14. Unno K, Sumiyoshi A, Konishi T, Hayashi M, Taguchi K, Muguruma
Y, et al. Theanine, the main amino acid in tea, prevents stress-induced
brain atrophy by modifying early stress responses. Nutrients. (2020)
12:174. doi: 10.3390/nu12010174
15. Doifode T, Giridharan VV, Generoso JS, Bhatti G, Collodel A,
Schulz PE, et al. The impact of the microbiota-gut-brain axis
on Alzheimer’s disease pathophysiology. Pharmacol Res. (2021)
164:105314. doi: 10.1016/j.phrs.2020.105314
16. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the
gut microbiota on brain and behaviour. Nat Rev Neurosci. (2012) 13:701–
12. doi: 10.1038/nrn3346
17. Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF. Late-
life depression and risk of vascular dementia and Alzheimer’s disease:
systematic review and meta-analysis of community-based cohort studies. Br
J Psychiatry. (2018) 202:329–35. doi: 10.1192/bjp.bp.112.118307
18. Diniz BS, Reynolds CF, Begley A, Dew MA, Anderson SJ, Lotrich F, et al.
Brain-derived neurotrophic factor levels in late-life depression and comorbid
mild cognitive impairment: a longitudinal study. J Psychiatr Res. (2014)
49:96–101. doi: 10.1016/j.jpsychires.2013.11.004
19. Florensa-Zanuy E, Garro-Martínez E, Adell A, Castro E, Díaz Á, Pazos Á,
et al. Cannabidiol antidepressant-like effect in the lipopolysaccharide model
Frontiers in Nutrition | www.frontiersin.org 7 May 2021 | Volume 8 | Article 669846
Businaro et al. Nutrition in Neurodegenerative Diseases and Depression
in mice: modulation of inflammatory pathways. Biochem Pharmacol. (2021)
185:114433. doi: 10.1016/j.bcp.2021.114433
20. Czéh B, Lucassen PJ. What causes the hippocampal volume decrease
in depression? Euro Arch Psychiatry Clin Neurosci. (2007) 257:250–
60. doi: 10.1007/s00406-007-0728-0
21. Gould E, Tanapat P, Rydel T, Hastings N. Regulation of
hippocampal neurogenesis in adulthood. Biol Psychiatry. (2000)
48:715–20. doi: 10.1016/S0006-3223(00)01021-0
22. Lucassen PJ, Meerlo P, Naylor AS, van Dam AM, Dayer AG,
Fuchs E, et al. Regulation of adult neurogenesis by stress, sleep
disruption, exercise and inflammation: implications for depression
and antidepressant action? Euro Neuropsychopharmacol. (2010)
20:1–17. doi: 10.1016/j.euroneuro.2009.08.003
23. Elvsåshagen T, Zuzarte P, Westlye LT, Bøen E, Josefsen D, Boye B, et al.
Dentate gyrus–cornu ammonis (CA) 4 volume is decreased and associated
with depressive episodes and lipid peroxidation in bipolar II disorder:
longitudinal and cross-sectional analyses. Bipolar Disord. (2016) 18:657–
68. doi: 10.1111/bdi.12457
24. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, et al.
Cytokine-Associated emotional and cognitive disturbances in humans. Arch
Gen Psychiatry. (2001) 58:445–52. doi: 10.1001/archpsyc.58.5.445
25. Ma K, Zhang H, Baloch Z, Pathogenetic and therapeutic applications of
tumor necrosis factor-α (TNF-α) in major depressive disorder: a systematic
review. Int J Mol Sci. (2016) 17:733. doi: 10.3390/ijms17050733
26. Lee KM, Kim YK. The role of IL-12 and TGF-β1 in the pathophysiology
of major depressive disorder. Int Immunopharmacol. (2006) 6:1298–
304. doi: 10.1016/j.intimp.2006.03.015
27. Myint A, Leonard B, Steinbusch H, Kim Y. Th1, Th2, and Th3
cytokine alterations in major depression. J Affect Disord. (2005) 88:167–
73. doi: 10.1016/j.jad.2005.07.008
28. Bonsall DR, Kim H, Tocci C, Ndiaye A, Petronzio A, McKay-Corkum G, et
al. Suppression of locomotor activity in female C57Bl/6J mice treated with
interleukin-1β: investigating a method for the study of fatigue in laboratory
animals. PLoS ONE. (2015) 10:e0140678. doi: 10.1371/journal.pone.0140678
29. Chong PS, Fung ML, Wong KH, Lim LW. Therapeutic potential
of hericium erinaceus for depressive disorder. Int J Mol Sci. (2019)
21:163. doi: 10.3390/ijms21010163
30. Raison CL, Miller AH. Role of inflammation in depression: implications
for phenomenology, pathophysiology and treatment. Mod Trends
Pharmacopsychiatry. (2013) 28:33–48. doi: 10.1159/000343966
31. Chen Z, Wu Y, Duan J, Yang L. The cholinergic anti-inflammatory pathway
could be an important mechanism underling the comorbidity of depression
and cardiovascular disease: a comment to shao et al. Psychiatry Res. (2020)
286:112881. doi: 10.1016/j.psychres.2020.112881
32. Shao M, Lin X, Jiang D, Tian H, Xu Y, Wang L, et al.
Depression and cardiovascular disease: shared molecular
mechanisms and clinical implications. Psychiatry Res. (2020)
285:112802. doi: 10.1016/j.psychres.2020.112802
33. Gunawardena D, Raju R, Münch G. Hydrogen peroxide mediates
pro-inflammatory cell-to-cell signaling: a new therapeutic
target for inflammation? Neur Regenerat Res. (2019) 14:1430–
7. doi: 10.4103/1673-5374.253529
34. Johnson JD, Barnard DF, Kulp AC, Mehta DM. Neuroendocrine regulation
of brain cytokines after psychological stress. J Endocrine Soc. (2019) 3:1302–
20. doi: 10.1210/js.2019-00053
35. Steiner N, Balez R, Karunaweera N, Lind JM, Münch G, Ooi L.
Neuroprotection of Neuro2a cells and the cytokine suppressive and
anti-inflammatory mode of action of resveratrol in activated RAW
264.7 macrophages and C8–B4 microglia. Neurochem Int. (2016) 95:46–
54. doi: 10.1016/j.neuint.2015.10.013
36. Neshatdoust S, Saunders C, Castle SM, Vauzour D,Williams C, Butler L, et al.
High-flavonoid intake induces cognitive improvements linked to changes in
serum brain-derived neurotrophic factor: two randomised, controlled trials.
Nutr Heal Aging. (2016) 4:81–93. doi: 10.3233/NHA-1615
37. Brites D, Fernandes A. Neuroinflammation and depression: microglia
activation, extracellular microvesicles and microRNA dysregulation. Front
Cell Neurosci. (2015) 9:476. doi: 10.3389/fncel.2015.00476
38. Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G,
et al. Identification of a unique TGF-β-dependent molecular and functional
signature in microglia.Nat Neurosci. (2013) 17:131–43. doi: 10.1038/nn.3599
39. Wolf SA, Boddeke HWGM, Kettenmann H. Microglia in
physiology and disease. Ann Rev Physiol. (2017) 79:619–
43. doi: 10.1146/annurev-physiol-022516-034406
40. Kim YK, Na KS, Myint A-M, Leonard BE. The role of pro-inflammatory
cytokines in neuroinflammation, neurogenesis and the neuroendocrine
system in major depression. Progr Neuro Psychopharmacol Biol Psychiatry.
(2016) 64:277–84. doi: 10.1016/j.pnpbp.2015.06.008
41. Cereseto M, Reinés A, Ferrero A, Sifonios L, Rubio M, Wikinski S.
Chronic treatment with high doses of corticosterone decreases cytoskeletal
proteins in the rat hippocampus. Euro J Neurosci. (2006) 24:3354–
64. doi: 10.1111/j.1460-9568.2006.05232.x
42. Levy A, Dachir S, Arbel I, Kadar T. Aging, stress, and
cognitive functiona. Ann N Y Acad Sci. (1994) 717:79–
88. doi: 10.1111/j.1749-6632.1994.tb12075.x
43. Linnemann C, Lang UE. Pathways connecting late-life depression and
dementia. Front Pharmacol. (2020) 11:279. doi: 10.3389/fphar.2020.00279
44. Fields C, Drye L, Vaidya V, Lyketsos C. Celecoxib or naproxen treatment
does not benefit depressive symptoms in persons age 70 and older: findings
from a randomized controlled trial. Am J Geriatr Psychiatry. (2012) 20:505–
13. doi: 10.1097/JGP.0b013e318227f4da
45. Husain MI, Chaudhry IB, Khoso AB, Husain MO, Hodsoll J, Ansari
MA, et al. Minocycline and celecoxib as adjunctive treatments for bipolar
depression: a multicentre, factorial design randomised controlled trial.
Lancet Psychiatry. (2020) 7:515–27. doi: 10.1016/S2215-0366(20)30138-3
46. Iyengar RL, Gandhi S, Aneja A, Thorpe K, Razzouk L, Greenberg
J, et al. NSAIDs are associated with lower depression scores in
patients with osteoarthritis. Am J Med. (2013) 126:1017.e11–
8. doi: 10.1016/j.amjmed.2013.02.037
47. Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-
Müller B, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic
effects in major depression: results of a double-blind, randomized, placebo
controlled, add-on pilot study to reboxetine. Mol Psychiatry. (2006) 11:680–
4. doi: 10.1038/sj.mp.4001805
48. Angeloni C, Businaro R, Vauzour D. The role of diet in preventing
and reducing cognitive decline. Curr Opin Psychiatry. (2020) 33:432–
8. doi: 10.1097/YCO.0000000000000605
49. Businaro R, Corsi M, Asprino R, Di Lorenzo C, Laskin D, Corbo RM,
et al. Modulation of inflammation as a way of delaying alzheimer’s
disease progression: the diet’s role. Curr Alzheimer Res. (2018) 15:363–
80. doi: 10.2174/1567205014666170829100100
50. Businaro R, Maggi E, Armeli F, Murray A, Laskin DL. Nutraceuticals as
potential therapeutics for vesicant-induced pulmonary fibrosis. Ann N Y
Acad Sci. (2020) 1480:5–13. doi: 10.1111/nyas.14442
51. Buttari B, Profumo E, Segoni L, D’Arcangelo D, Rossi S, Facchiano
F, et al. Resveratrol counteracts inflammation in human M1 and M2
macrophages upon challenge with 7-oxo-cholesterol: potential therapeutic
implications in atherosclerosis. Oxidat Med Cell Longev. (2014) 2014:1–
12. doi: 10.1155/2014/257543
52. De Caris MG, Grieco M, Maggi E, Francioso A, Armeli F, Mosca L, et al.
Blueberry counteracts BV-2 microglia morphological and functional switch
after LPS challenge. Nutrients. (2020) 12:1830. doi: 10.3390/nu12061830
53. Pinto A, Bonucci A, Maggi E, Corsi M, Businaro R. Anti-oxidant
and anti-inflammatory activity of ketogenic diet: new perspectives
for neuroprotection in alzheimer’s disease. Antioxidants. (2018)
7:63. doi: 10.3390/antiox7050063
54. Profumo E, Buttari B, Tinaburri L, D’Arcangelo D, Sorice M, Capozzi
A, et al. Oxidative stress induces HSP90 upregulation on the surface of
primary human endothelial cells: role of the antioxidant 7, 8-dihydroxy-
4-methylcoumarin in preventing HSP90 exposure to the immune system.
Oxidat Med Cell Longev. (2018) 2018:1–9. doi: 10.1155/2018/2373167
55. Sobolev, Ciampa, Ingallina, Mannina, Capitani, Ernesti, et al.
Blueberry-Based meals for obese patients with metabolic syndrome:
a multidisciplinary metabolomic pilot study. Metabolites. (2019)
9:138. doi: 10.3390/metabo9070138
Frontiers in Nutrition | www.frontiersin.org 8 May 2021 | Volume 8 | Article 669846
Businaro et al. Nutrition in Neurodegenerative Diseases and Depression
56. Versele R, Corsi M, Fuso A, Sevin E, Businaro R, Gosselet F, et al. Ketone
bodies promote amyloid-β1–40 clearance in a human in vitro blood–brain
barrier model. Int J Mol Sci. (2020) 21:934. doi: 10.3390/ijms21030934
57. Venigalla M, Gyengesi E, Münch G. Curcumin and apigenin - novel
and promising therapeutics against chronic neuroinflammation
in Alzheimer’s disease. Neur Regenerat Res. (2015) 10:1181–
5. doi: 10.4103/1673-5374.162686
58. Sarris J. Nutritional psychiatry: from concept to the clinic. Drugs. (2019)
79:929–34. doi: 10.1007/s40265-019-01134-9
59. Serhan CN. Pro-resolving lipidmediators are leads for resolution physiology.
Nature. (2014) 510:92–101. doi: 10.1038/nature13479
60. Brenna JT, Diau GY. The influence of dietary docosahexaenoic acid and
arachidonic acid on central nervous system polyunsaturated fatty acid
composition. Prostaglandins Leukot Essent Fatty Acids. (2007) 77:247–
50. doi: 10.1016/j.plefa.2007.10.016
61. Baierle M, Vencato P, Oldenburg L, Bordignon S, Zibetti M, Trentini C, et al.
Fatty acid status and its relationship to cognitive decline and homocysteine
levels in the elderly. Nutrients. (2014) 6:3624–40. doi: 10.3390/nu6093624
62. Pontifex M, Vauzour D, Minihane A-M. The effect of APOE
genotype on Alzheimer’s disease risk is influenced by sex
and docosahexaenoic acid status. Neurobiol Aging. (2018)
69:209–20. doi: 10.1016/j.neurobiolaging.2018.05.017
63. Fiala M, Kooij G, Wagner K, Hammock B, Pellegrini M. Modulation of
innate immunity of patients with Alzheimer’s disease by omega-3 fatty acids.
FASEB J. (2017) 31:3229–39. doi: 10.1096/fj.201700065R
64. Olivera-Perez HM, Lam L, Dang J, Jiang W, Rodriguez F, Rigali E, et al.
Omega-3 fatty acids increase the unfolded protein response and improve
amyloid-β phagocytosis by macrophages of patients with mild cognitive
impairment. FASEB J. (2017) 31:4359–69. doi: 10.1096/fj.201700290R
65. Simonetto M, Infante M, Sacco RL, Rundek T, Della-Morte D. A novel
anti-inflammatory role of omega-3 PUFAs in prevention and treatment of
atherosclerosis and vascular cognitive impairment and dementia. Nutrients.
(2019) 11:2279. doi: 10.3390/nu11102279
66. Boespflug EL, McNamara RK, Eliassen JC, Schidler MD, Krikorian R. Fish
oil supplementation increases event-related posterior cingulate activation in
older adults with subjective memory impairment. The journal of nutrition,
health & aging. (2015) 20:161–9. doi: 10.1007/s12603-015-0609-6
67. Yassine HN, Braskie MN, Mack WJ, Castor KJ, Fonteh AN, Schneider LS,
et al. Association of docosahexaenoic acid supplementation with Alzheimer
disease stage in apolipoprotein E4 carriers. JAMA Neurol. (2017) 74:339–
47. doi: 10.1001/jamaneurol.2016.4899
68. McGahon BM, Martin DSD, Horrobin DF, Lynch MA. Age-related
changes in synaptic function: analysis of the effect of dietary
supplementation with Omega-3 fatty acids. Neuroscience. (1999)
94:305–14. doi: 10.1016/S0306-4522(99)00219-5
69. Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, et
al. Effect of vitamin e and memantine on functional decline in alzheimer
disease. JAMA. (2014) 311:33–44. doi: 10.1001/jama.2013.282834
70. Manosso LM, Camargo A, Dafre AL, Rodrigues ALS. Vitamin E for
the management of major depressive disorder: possible role of the
anti-inflammatory and antioxidant systems. Nutr Neurosci. (2020) 1–
15. doi: 10.1080/1028415X.2020.1853417. [Epub ahead of print].
71. Mazereeuw G, Lanctôt KL, Chau SA, Swardfager W, Herrmann N. Effects
of omega-3 fatty acids on cognitive performance: a meta-analysis. Neurobiol
Aging. (2012) 33:1482.e17–29. doi: 10.1016/j.neurobiolaging.2011.12.014
72. Jernerén F, Elshorbagy AK, Oulhaj A, Smith SM, Refsum H, Smith AD.
Brain atrophy in cognitively impaired elderly: the importance of long-chain
Omega-3 fatty acids and B vitamin status in a randomized controlled trial.
Am J Clin Nutr. (2015) 102:215–21. doi: 10.3945/ajcn.114.103283
73. Oulhaj A, Jernerén F, Refsum H, Smith AD, de Jager CA. Omega-
3 fatty acid status enhances the prevention of cognitive decline by B
vitamins in mild cognitive impairment. J Alzheimers Dis. (2016) 50:547–
57. doi: 10.3233/JAD-150777
74. Kurilshikov A, Medina-Gomez C, Bacigalupe R, Radjabzadeh D, Wang J,
Demirkan A, et al. Large-scale association analyses identify host factors
influencing human gut microbiome composition. Nat Genet. (2021) 53:156–
65. doi: 10.1038/s41588-020-00763-1
75. O’Toole PW, Jeffery IB. Gut microbiota and aging. Science. (2015) 350:1214–
5. doi: 10.1126/science.aac8469
76. Human Microbiome Project. Available online at: https://commonfund.nih.
gov/hmp (accessed April 29, 2021).
77. Parolini C. Effects of fish n-3 PUFAs on intestinal microbiota and immune
system.Mar Drugs. (2019) 17:374. doi: 10.3390/md17060374
78. Mediavilla C. Bidirectional gut-brain communication: a role for orexin-A.
Neurochem Int. (2020) 141:104882. doi: 10.1016/j.neuint.2020.104882
79. Boulle F, van den Hove DLA, Jakob SB, Rutten BP, Hamon M, van Os J,
et al. Epigenetic regulation of the BDNF gene: implications for psychiatric
disorders.Mol Psychiatry. (2011) 17:584–96. doi: 10.1038/mp.2011.107
80. Wu X, Chen PS, Dallas S, Wilson B, Block ML, Wang C
C, et al. Histone deacetylase inhibitors up-regulate astrocyte
GDNF and BDNF gene transcription and protect dopaminergic
neurons. Int J Neuropsychopharmacol. (2008) 11:1123–
34. doi: 10.1017/S1461145708009024
81. Tran TTT, Corsini S, Kellingray L, Hegarty C, Le Gall G, Narbad A, et al.
APOE genotype influences the gut microbiome structure and function in
humans andmice: relevance for Alzheimer’s disease pathophysiology. FASEB
J. (2019) 33:8221–31. doi: 10.1096/fj.201900071R
82. Maldonado Weng J, Parikh I, Naqib A, York J, Green SJ, Estus S,
et al. Synergistic effects of APOE and sex on the gut microbiome
of young EFAD transgenic mice. Mol Neurodegenerat. (2019)
14:47. doi: 10.1186/s13024-019-0352-2
83. Larsen N, Vogensen FK, van den Berg FWJ, Nielsen DS, Andreasen
AS, Pedersen BK, et al. Gut microbiota in human adults with
type 2 diabetes differs from non-diabetic adults. PLoS ONE. (2010)
5:e9085. doi: 10.1371/journal.pone.0009085
84. Huang TL, Zandi PP, Tucker KL, Fitzpatrick AL, Kuller LH, Fried LP, et al.
Benefits of fatty fish on dementia risk are stronger for those without APOE4.
Neurology. (2005) 65:1409–14. doi: 10.1212/01.wnl.0000183148.34197.2e
85. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck
C, et al. Docosahexaenoic acid supplementation and cognitive decline in
Alzheimer disease. JAMA. (2010) 304:1903–11. doi: 10.1001/jama.2010.1510
86. Arellanes IC, Choe N, Solomon V, He X, Kavin B, Martinez AE,
et al. Brain delivery of supplemental docosahexaenoic acid (DHA):
a randomized placebo-controlled clinical trial. EBioMedicine. (2020)
59:102883. doi: 10.1016/j.ebiom.2020.102883
87. Metherel AH, Irfan M, Klingel SL, Mutch DM, Bazinet RP.
Compound-specific isotope analysis reveals no retroconversion of
DHA to EPA but substantial conversion of EPA to DHA following
supplementation: a randomized control trial. Am J Clin Nutr. (2019)
110:823–31. doi: 10.1093/ajcn/nqz097
88. Martinsen A, Tejera N, Vauzour D, Harden G, Dick J, Shinde S, et al. Altered
SPMs and age-associated decrease in brain DHA in APOE4 female mice.
FASEB J. (2019) 33:10315–26. doi: 10.1096/fj.201900423R
89. Firth J, Teasdale SB, Allott K, Siskind D, Marx W, Cotter J, et al. The
efficacy and safety of nutrient supplements in the treatment of mental
disorders: a meta-review of meta-analyses of randomized controlled trials.
World Psychiatry. (2019) 18:308–24. doi: 10.1002/wps.20672
90. Maltais M, de Souto Barreto P, Pothier K, Cantet C, Andrieu S, Rolland Y,
et al. Lifestyle multidomain intervention, omega-3 supplementation, or both
for reducing the risk of developing clinically relevant depressive symptoms in
older adults with memory complaints? Secondary analysis from the MAPT
trial. Exp Gerontol. (2019) 120:28–34. doi: 10.1016/j.exger.2019.02.010
91. McPhilemy G, Byrne F, Waldron M, Hibbeln JR, Davis J, McDonald
C, et al. A 52-week prophylactic randomised control trial of omega-
3 polyunsaturated fatty acids in bipolar disorder. Bipolar Disord.
(2021). doi: 10.1111/bdi.13037. [Epub ahead of print].
92. Suradom C, Suttajit S, Oon-arom A, Maneeton B, Srisurapanont M. Omega-
3 polyunsaturated fatty acid (n-3 PUFA) supplementation for prevention
and treatment of perinatal depression: a systematic review and meta-
analysis of randomized-controlled trials. Nord J Psychiatry. (2020) 1–
8. doi: 10.1080/08039488.2020.1843710. [Epub ahead of print].
93. Thesing CS, Milaneschi Y, Bot M, Brouwer IA, Owens M, Hegerl U, et al.
Supplementation-induced increase in circulating omega-3 serum levels is
not associated with a reduction in depressive symptoms: results from the
Frontiers in Nutrition | www.frontiersin.org 9 May 2021 | Volume 8 | Article 669846
Businaro et al. Nutrition in Neurodegenerative Diseases and Depression
MooDFOOD depression prevention trial. Depress Anxiety. (2020) 37:1079–
88. doi: 10.1002/da.23092
94. Balachandar R, Soundararajan S, Bagepally BS. Docosahexaenoic
acid supplementation in age-related cognitive decline: a systematic
review and meta-analysis. Euro J Clin Pharmacol. (2020)
76:639–48. doi: 10.1007/s00228-020-02843-x
95. Giudici KV, de Souto Barreto P, Beard J, Cantet C, Araujo de Carvalho
I, Rolland Y, et al. Effect of long-term omega-3 supplementation
and a lifestyle multidomain intervention on intrinsic capacity
among community-dwelling older adults: secondary analysis of a
randomized, placebo-controlled trial (MAPT study). Maturitas. (2020)
141:39–45. doi: 10.1016/j.maturitas.2020.06.012
96. Rolland Y, Barreto PdS, Maltais M, Guyonnet S, Cantet C, Andrieu S, et
al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation
with or without multidomain lifestyle intervention on muscle strength in
older adults: secondary analysis of the multidomain alzheimer preventive
trial (MAPT). Nutrients. (2019) 11:1931. doi: 10.3390/nu11081931
97. Chew EY, Clemons TE, Agrón E, Launer LJ, Grodstein F, Bernstein
PS. Effect of omega-3 fatty acids, lutein/zeaxanthin, or other
nutrient supplementation on cognitive function. Jama. (2015)
314:791–801. doi: 10.1001/jama.2015.9677
98. Soininen H, Solomon A, Visser PJ, Hendrix SB, Blennow K, Kivipelto M, et
al. 36-month LipiDiDietmultinutrient clinical trial in prodromal Alzheimer’s
disease. Alzheimers Dement. (2020) 17:29–40. doi: 10.1002/alz.12172
99. Sarris J, Murphy J, Mischoulon D, Papakostas GI, Fava M, Berk M, et al.
Adjunctive nutraceuticals for depression: a systematic review and meta-
analyses. Focus. (2018) 16:328–40. doi: 10.1176/appi.focus.16304
100. Fuso A, Nicolia V, Cavallaro RA, Ricceri L, D’Anselmi F, Coluccia P,
et al. B-vitamin deprivation induces hyperhomocysteinemia and brain S-
adenosylhomocysteine, depletes brain S-adenosylmethionine, and enhances
PS1 and BACE expression and amyloid-β deposition in mice. Mol Cell
Neurosci. (2008) 37:731–46. doi: 10.1016/j.mcn.2007.12.018
101. Luo X-d, Feng J-s, Yang Z, Huang Q-t, Lin J-d, Yang B, et al.
High-dose omega-3 polyunsaturated fatty acid supplementation might
be more superior than low-dose for major depressive disorder in
early therapy period: a network meta-analysis. BMC Psychiatry. (2020)
20:248. doi: 10.1186/s12888-020-02656-3
102. Mischoulon D, Nierenberg AA, Schettler PJ, Kinkead BL, Fehling K,
Martinson MA, et al. A double-blind, randomized controlled clinical
trial comparing eicosapentaenoic acid versus docosahexaenoic acid for
depression. J Clin Psychiatry. (2015) 76:54–61. doi: 10.4088/JCP.14m08986
103. Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker
R, et al. Inflammation as a predictive biomarker for response to omega-3 fatty
acids in major depressive disorder: a proof-of-concept study.Mol Psychiatry.
(2015) 21:71–9. doi: 10.1038/mp.2015.22
104. Guu TW, Mischoulon D, Sarris J, Hibbeln J, McNamara Robert K, Hamazaki
K, et al. International society for nutritional psychiatry research practice
guidelines for omega-3 fatty acids in the treatment of major depressive
disorder. Psychother Psychosom. (2019) 88:263–73. doi: 10.1159/000502652
105. Sarris J, Freeman MP. Omega-3 fatty acid supplementation for
perinatal depression and other subpopulations? J Clin Psychiatry. (2020)
81:20com13489. doi: 10.4088/JCP.20com13489
106. Ali T, Hao Q, Ullah N, Rahman SU, Shah FA, He K, et al. Melatonin
act as an antidepressant via attenuation of neuroinflammation by
targeting Sirt1/Nrf2/HO-1 signaling. Front Mol Neurosci. (2020)
13:96. doi: 10.3389/fnmol.2020.00096
107. Cope EC, Levenson CW. Role of zinc in the development and treatment
of mood disorders. Curr Opin Clin Nutr Metab Care. (2010) 13:685–
9. doi: 10.1097/MCO.0b013e32833df61a
108. Anbari-Nogyni Z, Bidaki R, Madadizadeh F, Sangsefidi ZS, Fallahzadeh
H, Karimi-Nazari E, et al. Relationship of zinc status with depression
and anxiety among elderly population. Clin Nutr ESPEN. (2020) 37:233–
9. doi: 10.1016/j.clnesp.2020.02.008
109. Wang J, Um P, Dickerman B, Liu J. Zinc, magnesium, selenium
and depression: a review of the evidence, potential mechanisms
and implications. Nutrients. (2018) 10:584. doi: 10.3390/nu100
50584
110. Owen AJ, Batterham MJ, Probst YC, Grenyer BFS, Tapsell LC. Low plasma
vitamin E levels in major depression: diet or disease? Euro J Clin Nutr. (2004)
59:304–6. doi: 10.1038/sj.ejcn.1602072
Conflict of Interest: JS has received either presentation honoraria, travel support,
clinical trial grants, book royalties, or independent consultancy payments from:
Integria Healthcare & MediHerb, Pfizer, Scius Health, Key Pharmaceuticals, Taki
Mai, Fiji Kava, FIT-BioCeuticals, Blackmores, Soho-Flordis, Healthworld,
HealthEd, HealthMasters, Kantar Consulting, Angelini Pharmaceuticals,
Grunbiotics, Polistudium, Australian Natural Therapeutics Group, Research
Reviews, Elsevier, Chaminade University, International Society for Affective
Disorders, Complementary Medicines Australia, SPRIM, Terry White Chemists,
ANS, Society for Medicinal Plant and Natural Product Research, Sanofi-Aventis,
Omega-3 Center, the National Health and Medical Research Council, CR Roper
Fellowship. EG has received grants or PhD fellowship support from Indena Italy
SpA and Verdure Sciences. LB is employed in Polistudium, Italy, which received
funds for editorial assistance from Angelini. GM has received either presentation
honoraria, travel support, grants, or independent consultancy payments from
Polistudium, Integria Healthcare, Qbiotics, Soho-Floris, and Pharmako Ltd.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2021 Businaro, Vauzour, Sarris, Münch, Gyengesi, Brogelli and Zuzarte.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Nutrition | www.frontiersin.org 10 May 2021 | Volume 8 | Article 669846
